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HOT - MELT EXTRUSION OF MODIFIED materials , and the one or more hydrophobic fusible carriers 
RELEASE MULTI - PARTICULATES in an extruder to form the blend and extruding the blend 
through the extruder . Again , the release profile is determined 
CROSS - REFERENCE TO RELATED by the type of melt - extrusion and it fails to address the need 
APPLICATIONS 5 for the release of drugs that are in fragile multiparticulates . 
Again , the drug release in this patent is governed by the 
This application is a continuation of U . S . application Ser . properties of the thermoplastic carrier polymer and not by 
No . 12 / 544 , 963 , filed Aug . 20 , 2009 , which claims benefit of the particles . 
priority to U . S . Provisional application Ser . Nos . 61 / 090 . 439 One approach as disclosed in patent application WO 
and 61 / 107 . 027 filed on Aug . 20 . 2008 , and Oct . 21 . 2008 . 10 2008 / 101743 ( Gryczke 2008 ) involves the blending of an 
respectively . The entire contents of each of the applications anionic polymer exhibiting a low glass transition tempera 
referenced above are hereby incorporated by reference . ture but too high permeability ( Eudragit FS ) with a water 
insoluble polymer ( Eudragit RS , RL or NE ) to reduce the 
TECHNICAL FIELD OF THE INVENTION release in acid . 
15 
The present invention relates in general to the field of SUMMARY OF THE INVENTION 
controlled release of active agents , and more particularly , to 
compositions and methods for making hot - melt extrusions This invention provides compositions and methods for 
including modified release multi - particulates . their preparation by embedding modified release multi 
20 particulates in a matrix under preservation of the dissolution 
STATEMENT OF FEDERALLY FUNDED characteristics of the original modified release multi - par 
RESEARCH ticulates . The present invention combines the benefits of a 
monolithic dosage form that releases multiple unit dosage 
None . systems after administration . It has been found that the 
25 present invention overcomes some or all of the problems 
BACKGROUND OF THE INVENTION that occur with alternative methods that may be used to 
formulate modified release multi - particulates into mono 
Without limiting the scope of the invention , its back lithic systems such as compression into tablets or filling into 
ground is described in connection with the controlled release capsules . These shortcomings include one or more of the 
of active agents , e . g . , pharmaceutical agents . 30 following : ( 1 ) problems of content uniformity of the final 
One such patent is U . S . Pat . No . 6 , 335 , 033 , issued to product , especially but not only at low loading levels ; ( 2 ) 
Oshlack , et al . for melt - extrusion of multiparticulates in changes in the drug dissolution profile of the final product 
which a unit dose sustained - release oral dosage form is compared to the unprocessed multi - particulates due to inter 
taught containing a plurality of melt - extruded particles , each ference with release controlling principles such as polymeric 
consisting essentially of a therapeutically active agent , one 35 coating or matrices during the embedment process ; ( 3 ) 
or more retardants , and optional water - insoluble binders . limited loading of the monolithic system with multi - particu 
The particles have a length of from about 0 . 1 to about 12 mm lates due to the requirement of large amounts of excipients 
and can be of varying diameters and each unit dose provides to aid the embedment process or to protect the release 
a release of therapeutically active agents over at least about characteristics of the multi - particulates ; ( 4 ) sensitivity of the 
8 hours . Methods of preparing the unit doses as well as 40 final product to moisture due to the permeability of the 
extrusion processes and methods of treatment are also matrix - forming principle ; and ( 5 ) possibility of tampering 
disclosed . However , the release profile is determined by the with the final product . 
type of melt - extrusion . Furthermore , the melt - extrusion pro - In one embodiment the present invention describes a 
cess fails to address the need for the release of drugs that are controlled release pharmaceutical formulation comprising 
in fragile multiparticulates . The drug release in this patent is 45 one or more modified release multi - particulates having an 
governed by the properties of the thermoplastic carrier effective amount of one or more therapeutic compounds , 
polymer and not by the particles . wherein the multi - particulates comprise a known drug 
Yet another patent is U . S . Pat . No . 6 , 743 , 442 , issued to release profile and are thermally processed into an extrudate 
Oshlack , et al . for melt - extruded orally administrable opioid in a thermoplastic polymer matrix , a lipid material or both 
formulations . Briefly , a bioavailable sustained release oral 50 wherein the thermal processing conditions maintain the 
opioid analgesic dosage form is described comprising a majority of the known drug release profile of the multi 
plurality of multiparticulates produced via melt extrusion particulates upon release from the thermoplastic polymer 
techniques . This patent claims a sustained - release pharma - matrix or the lipid material . 
ceutical formulation comprising an extruded blend of a The extrudate as described in the present invention com 
therapeutically active agent , one or more hydrophobic mate - 55 prises at least 80 % intact multi - particulates , wherein the 
rials selected from the group consisting of alkylcelluloses , multi - particulates comprise a polymeric film coat . In one 
acrylic polymers , and mixtures thereof ; and one or more aspect the controlled release pharmaceutical formulation 
hydrophobic fusible carriers having a melting point from comprising multi - particulates with an inherent drug - release 
about 30° to about 200° C . and selected from the group controlling or a drug - protection principle comprises a poly 
consisting of natural or synthetic waxes , fatty acids , fatty 60 meric matrix or a hydrophobic material . In another aspect 
alcohols , and mixtures thereof , the extruded blend divided the multi - particulates comprise an enteric drug release coat 
into a unit dose containing an effective amount of the ing . In yet another aspect the multi - particulates are coated 
therapeutically active agent to render a desired therapeutic for an extended release and moisture protection of the one or 
effect and providing a sustained - release of the therapeuti - more therapeutic compounds . 
cally active agent for a time period of from about 8 to about 65 In another aspect the modified release multi - particulates 
24 hours , the extruded blend being formed by mixing the are coated with an additional water - soluble or acid - soluble 
therapeutically active agent , the one or more hydrophobic coat and are processed to minimize an incompatibility 
US 9 , 827 , 202 B2 
between the one or more therapeutic compounds and one or pharmaceutically active substance is released after 2 hours 
more excipients present in the matrix . The water - soluble or in a simulated gastric fluid pH 1 . 2 and at least 40 % after 2 
acid - soluble coat comprises a polymer selected from the additional hours in a pH 6 . 8 buffer or a pH 7 . 4 buffer . In 
group consisting of polymethacrylates , cellulose derivatives , another aspect more than 60 % of the pharmaceutically 
polysaccharides , proteins , or vinyl polymers . In other 5 active substance is released after 2 hours in the pH 6 . 8 buffer 
aspects the multi - particulates are film - coated drug granules , or the pH 7 . 4 buffer . 
film - coated drug - loaded pellets or film - coated drug - layered In a specific aspect the average particle size of the one or 
nonpareils . In specific aspects the multi - particulates are in a more modified release pellets is between 500 and 1000 um . 
size range of 50 - 800 um , preferably 300 - 500 um and the The particle size of the one or more modified release pellets 
polymeric film coat of the multi - particulates comprises 10 as described by the embodiment of the present invention is 
between 10 % to 60 % polymer ( s ) ( w / w ) , more preferably 200 , 300 , 400 , 500 , 600 , 750 , 800 , 1000 , 1500 , 2000 , 2500 , 
20 - 50 % , based on an uncoated weight of the multi - particu - 3000 and 5000 um . 
lates . In one aspect a weight percentage of the pharmaceutically 
In another aspect the one or more polymers in the poly - active substance is between 0 . 1 - 70 % . In another aspect the 
meric film coat are selected from the group consisting of 15 weight percentage of the pharmaceutically active substance 
polymethacrylates , cellulose derivatives , polysaccharides , is between 5 - 40 % . In yet another aspect the weight percent 
proteins , or vinyl polymers , and may be plasticized . In yet age of the pharmaceutically active substance is 0 . 1 , 0 . 5 , 1 , 
another aspect the multi - particulates comprise between 5 to 2 , 3 , 4 , 5 , 10 , 20 , 30 , 40 , 50 , 60 , 70 , and 80 % . The one or 
80 weight percent of the one or more therapeutic com more anionic polymers is a copolymer of methacrylate and 
pounds . In another aspect the thermoplastic polymer matrix 20 methacrylic acid , wherein the one or more anionic polymers 
comprises one or more components that are at least partially are selected from the group consisting of acrylic acid , 
crystalline polymers with a melting point below 80° C . The methyacrylic acid , vinyl acetic acid , crotonic acid , ally 
thermoplastic polymers used in the present invention is lacetic acid , 4 - methyl - 4 pentonic acid , vinyl sulfonate , sty 
selected from the group consisting of poly ( ethylene oxide ) - rene sulfonate and acrylamido methyl propane sulfonic acid . 
polypropylene oxide ) copolymer , poly ( ethylene glycol ) or 25 The copolymer contains at least 20 % methacrylic acid . 
poly ( ethylene oxide ) having a molecular weight less than In one aspect the one or more modified release pellets can 
about 1 , 000 , 000 . In specific aspects the weight percent of the withstand a load of at least 10N without undergoing a 
multi - particulates is 5 to 70 weight percent . The polymer fracture or a deformation . In another aspect the one or more 
matrix may dissolve , disintegrate or swell in dissolution modified release pellets are transferred to a monolithic 
medium , an aqueous medium to release the modified release 30 system comprising a tablet , a capsule or any combinations 
multi - particulates or enable drug release from the multi thereof . 
particulates by diffusion . In one embodiment the present invention describes a 
The modified release multi - particulates of the present method of preparing a controlled release pharmaceutical 
invention are further defined as comprising enteric polymers formulation comprising the step of mixing one or more 
or water insoluble modified release polymers that control the 35 modified release multi - particulates comprising an effective 
drug release by diffusion or pH - dependent polymer disso - amount of a therapeutic compound having a known drug 
lution . Delayed release articles may be prepared by process release profile with a thermoplastic polymer matrix or 
ing modified release multi - particulates that are enterically hydrophilic wax containing matrix by thermal processing 
coated , with less than 10 % drug released in acidic media under conditions that preserve a drug - release controlling , a 
from the dosage form comprising the enteric coated modi - 40 drug - protection characteristic or both of the multi - particu 
fied release multi - particulates , and when media is switched lates . In one aspect the thermal processing is performed by 
to a pH above 6 . 8 , greater than 80 % drug is released in 45 a hot - melt extrusion , conducted with a single - screw or a 
minutes in a buffer media outlined in the U . S . P . twin screw extruder at temperatures of less than about 100° 
In one aspect the modified release multi - particulates fur - C . 
ther comprise a retardant matrix , wherein the retardant 45 In another aspect the multi - particulates comprise a film 
matrix erodes or disintegrates to release the modified release coat that is applied by a dry coating process , an aqueous 
multi - particulates . In another aspect both the matrix and the coating process or by a solvent coating process . In yet 
modified release multi - particulates are film - coated , matrix another aspect the multi - particulates are coated in a fluidized 
coated or both . bed - coater . Sustained release multiparticulates may be 
In another embodiment the present invention is a con - 50 obtained by coating with at least one of hydrophobic poly 
trolled release pharmaceutical formulation comprising one mers , hydrophilic polymers , gums , protein derived materi 
or more modified release multi - particulates having an effec - als , waxes , shellac , oils and mixtures thereof . 
tive amount of one or more therapeutic compounds , wherein In another embodiment the present invention describes a 
the multi - particulates comprise a known drug release profile pharmaceutical solid dosage form providing a controlled 
and are thermally processed into an extrudate in a thermo - 55 release of the therapeutic compound and comprising the 
plastic polymer matrix , a lipid material or both , under pharmaceutical formulation prepared according to the 
thermal processing conditions that maintain integrity of the method of the present invention . In one aspect the preferred 
multi - particulates during processing . The extrudate as site of administration of the composition described in the 
described by the embodiment of the present invention com - present invention is an oral route . In another aspect the 
prises at least 80 % intact multi - particulates . 60 controlled release is further defined as immediate , extended 
In another embodiment the present invention discloses a or delayed release . 
controlled release pharmaceutical formulation comprising In yet another embodiment the present invention discloses 
one or more modified release pellets with an average particle a method of preparing a controlled release pharmaceutical 
size of 300 - 3000 um , wherein the one or more modified formulation comprising one or more modified release cylin 
release pellets comprise a pharmaceutically active substance 65 drical pellets comprising the steps of : ( i ) mixing a pharma 
embedded in a matrix of one or more anionic polymers and ceutically active substance , one or more anionic polymers , 
a processing aid . In one aspect , less than 10 % of the and a processing aid to form a mixture , ( ii ) processing the 
US 9 , 827 , 202 B2 
de ete 
mixture with a hot - melt extrusion process to form one or be appreciated that the present invention provides many 
more extruded strands , and ( iii ) cutting the extruded strand applicable inventive concepts that can be embodied in a 
to form the one or more modified release cylindrical pellets . wide variety of specific contexts . The specific embodiments 
The method as described in the embodiment of the present discussed herein are merely illustrative of specific ways to 
invention further comprises the steps of applying a poly - 5 make and use the invention and do not delimit the scope of 
meric film coat to the one or more modified release cylin - the invention . 
drical pellets and spheronizing the one or more modified To facilitate the understanding of this invention , a number release cylindrical pellets . of terms are defined below . Terms defined herein have In one aspect the temperature during the hot - melt extru meanings as commonly understood by a person of ordinary sion process does not exceed 200° C . In another aspect the 10 skill in the areas relevant to the present invention . Terms temperature of at least one of the heating zones during the such as " a " , " an " and " the " are not intended to refer to only hot - melt extrusion process exceeds a glass transition tem a singular entity , but include the general class of which a perature of the polymer by at least 10° C . 
In one embodiment the present invention is a method for specific example may be used for illustration . The terminol spe ogy herein is used to describe specific embodiments of the 
a controlled release pharmaceutical formulation comprising : 15 invention , but their usage does not delimit the invention , 
selecting one or more modified release multi - particulates except as outlined in the claims . 
with an effective amount of one or more therapeutic com The present invention includes compositions and methods 
pounds having a known drug - release profile , mixing the one of making a modified release pharmaceutical formulation 
or more modified release multi - particulates with a thermo - and a method of preparation for the embedding of modified 
plastic polymer matrix or hydrophilic wax containing 20 release multi - particulates into a polymeric or wax - like 
matrix , extruding the multi - particulates with the thermoplas matrix . The polymer matrix comprises a thermoplastic poly 
tic polymer matrix or the hydrophilic wax containing matrix mer or lipophilic carrier or a mixture thereof that softens or 
under varying conditions to form an extrudate , determining melts at elevated temperature and allows the distribution of 
a drug release profile for the extrudate , and selecting the the modified release multi - particulates in the polymer matrix 
thermoplastic polymer matrix or the hydrophilic wax con - 25 during thermal processing . 
taining matrix and the extruding conditions in which at least The present invention further details a formulation and 80 % of the one or more modified release multi - particulates method of preparation for pellets having a mean particle size maintain the known drug release profile . of 300 - 3000 um , comprising a pharmaceutically active 
substance in a matrix comprising an anionic polymer and BRIEF DESCRIPTION OF THE DRAWINGS 30 one or more plasticizers . The pellets provide a drug release 
For a more complete understanding of the features and of less than 10 % in simulated gastric fluid over 2 hours , and of 
advantages of the present invention , reference is now made release at least 40 % after another 2 hours in buffer of pH 6 . 8 
to the detailed description of the invention along with the 
accompanying figures and in which : The preparation of enteric pellets traditionally involves 
FIG . 1 shows a cross - section of an exemplary embodi - 35 several processing steps including wet - massing and extru 
ment of a hot - melt extruded composition as provided by the sion , spheronization and functional coating . Theses methods 
invention ; require the use of organic or aqueous solvents and time - and 
FIG . 2 is a graph of drug release profiles for compositions cost intensive drying procedures . The pellets manufactured 
prepared according to Examples 2 , 4 and 7 and tested according to these traditional methods usually exhibit low 
according to Example 9 ; 40 mechanical strength and high friability . The process of 
FIG . 3 is a graph of drug release profiles for compositions hot - melt extrusion of the present invention allows the manu 
prepared according to Examples 2 , 4 and 7 and tested facture of enteric matrix pellets in a single step and con 
according to Example 9 . The pellet load in the matrix was tinuous manner avoiding subsequent film coating and 
30 % ; abstaining from the use of organic solvents . A powder blend 
FIG . 4 shows the drug release after 2 hours in medium pH 45 comprising the drug , an anionic polymer and optional pro 
1 . 2 for different multi - particulates according to Examples cessing aids is mixed , melted and transported inside a heated 
1 - 4 and tested according to Example 9 before extrusion and barrel by one or two rotating screws before exiting through 
after extrusion of 30 % multi - particulates in Poloxamer 407 a product - shaping die . Besides technological advantages , 
according to Example 7 ; hot - melt extruded pellets allow the incorporation of higher 
FIG . 5 is a graph of drug release profiles for compositions 50 drug loadings under preservation of the controlled release 
prepared with 30 % granules as defined in Example 1 and properties which is attributed to the low porosity of melt 
coated according to Example 4 after processing according to extruded matrices when compared to pellets prepared by 
Example 7 in Poloxamer 407 or Example 8 when tested traditional wet - massing techniques " . Melt - extruded pellets 
according to Example 9 ; and further exhibit low friability , high mechanical strength and 
FIG . 6 is a graph of drug release profiles for a composition 55 enhanced robustness of the release properties during down 
prepared with 30 % granules as defined in Example 1 and stream processing such as direct compression into single 
coated according to Example 4 after processing according to unit tablets . 
Example 7 in Poloxamer 407 when tested according to The successful preparation of sustained release pellets by 
Example 9 immediately after preparation and after 1 year of hot - melt extrusion has been reported in several publica 
storage at room temperature ( 22 + 1°C . ) and ambient relative 60 tions - and patents 6 - 7 . However , the manufacture of enteric 
humidity . pellets exhibiting a release of less than 10 % after 2 hours in 
simulated gastric fluid remains challenging . Attributed to the 
DETAILED DESCRIPTION OF THE larger surface area of small pellets , drug release in acid will 
INVENTION be increased when compared to tablets as previously dem 
65 onstrated for melt extruded Eudragit L100 - 55 matrices con 
While the making and using of various embodiments of taining 20 % drug® . Another aggravating circumstance to 
the present invention are discussed in detail below , it should overcome is the opposing trend between polymer perme 
US 9 , 827 , 202 B2 
ability and processibility . Anionic polymers with low glass The swellable polymer hydrated during dissolution and was 
transition temperatures and low melt viscosities produce postulated to act as a sealant for cracks formed in the coat 
pellets that are too permeable in acid and release more than during compression . 
10 % of the drug content . On the other hand , polymers The addition of cushioning agents such as wax / starch 
exhibiting low permeability and good protection in acid are 5 beads prepared by melt pelletization at a concentration of 
difficult to process by hot - melt extrusion due to their high 50 % w / w in the final tablet was demonstrated to reduce 
glass transition temperature and high melt viscosity . damage of diltiazem hydrochloride pellets coated with 
Dosage forms comprising multi - particulates provide Eudragit NE 30D13 . A similar strategy was applied by 
advantages over monolithic dosage forms . These advantages Debunne and colleagues to retain the dissolution character 
comprise improved distribution along the GI tract and the 10 istics of coated piroxicam pellets after compression14 . 
potential of enhanced bioavailability and more constant Enteric pellets coated only with plasticized Eudragit L30D 
blood plasma levels , the avoidance of high local and pos - 55 provided sufficient gastric protection over 2 hours , but the 
sible toxic drug concentration , a reduced risk of dose dump - amount of waxy pellets was required to exceed the load of 
ing , a decreased susceptibility of the drug absorption to food functional pellets s . Furthermore , the preparation of these 
effects or physiological factors , faster and less variable 15 cushioning particles is labor and cost intensive and may 
pharmacological effects due to more reproducible gastric interfere with the disintegration of the tablet . The utilization 
transit times and expanded formulation flexibility by mixing of granules with high porosity as tabletting excipient for 
of particles providing different actives or release rates . Post pellets was also shown to reduce the formation of indentions 
processing of multi - particulates is necessary to provide the into the pellet surface , but could not prevent deformation by 
patient with a conveniently administrable dosage form . 20 flattening of surfaces during compression . The efficiency 
Monolithic systems such as tablets or capsules may be used of tabletting additives to act as cushioning agents is further 
as the final dosage form and such solid compositions offer limited by their particle size . A study conducted by Yao et al . 
advantages over liquid formulations regarding storage sta with ethylcellulose coated theophylline powder demon 
bility , safety and patient compliance . strated that tabletting excipients with smaller particle size 
The two most common techniques include the filling of 25 were superior to protect the film from damage attributed to 
multi - particulates into capsules or the compression into their efficient cushioning ability during compression ! ) . 
tablets . The applicability of both procedures is compromised As detailed above , particle deformation under compres 
due to numerous short - comings . Capsules are more cost - sion causes rupture of functional films . Film cracking is a 
intensive than tablets and may be less secure due to their function of particle loading in the tablet and limits the 
higher susceptibility to tampering . Capsule shells are hydro - 30 applicability of compression methods for high loadings of 
scopic and provide little protection to light , oxygen and multi - particulates . It has been reported that up to approxi 
moisture . They are difficult to open and consequently pro - mately 30 % w / w particle loading - only multi - particulates at 
vide less flexibility in dosing options . the surface are affected by deformation and hence film 
Tabletting involves the exposure of the multi - particulates damagelº . Higher loading amounts will result in additional 
to high unidirectional compaction forces that may cause coat 35 particle deformation in the interior of the tablets because the 
rupture and / or particle deformation and fracture . It has been hard particle surfaces are in contact with each other . The 
reported that a strong particle core is necessary to prevent disintegration into the individual multi - particulates will fur 
cracking of Surelease E - 7 - 7050 and Methocel A4C coats ther be inhibited by particle fusion during compression . This 
applied to Theophylline - comprising pellets " . The applica phenomenon also limits the applicability of high particle 
tion of a film coat did not change the strength of the drug 40 loadings . 
pellet , regardless of the coat thickness . The core of the Tabletting of multi - particulates is further challenging due 
multi - particulates fractured before the coat broke , and was to differences in particle size , particle shape and true density 
followed by coat rupture when the crushed core was between the particles and the tabletting additives . The con 
deformed under the compression load . Beckert and cowork tent uniformity of the final dosage form may be compro 
ers reported an enhanced release of bisacodyl from enteric 45 mised by blend segregation and poor powder flow during 
coated pellets in acidic media when soft pellets with low tabletting . Different strategies have been employed to over 
crushing strength were used as opposed to hard pellets . come shortcomings concerning content uniformity such as 
Sufficient rupture strength of the coat is further necessary coating of the tabletting excipients directly onto the coated 
to resist film damage at low degrees of particle deformation . pellets 18 , processing of the tabletting excipients into placebo 
Therefore , brittle polymers do not qualify for the application 50 pellets of the same sizelor utilizing fillers of small particle 
as coating materials unless high coating levels are used . size20 . Most of theses approaches involve further prepara 
Alternatively , high amounts of plasticizer must be added to tion steps resulting in increased operating expenses . Beckert 
increase the film flexibility during compression , but these and coworkers investigated the influence of the pellet per 
substances may leach from the product during storage . The centage in the tablet formulation on the content unifor 
flexibility of Eudragit L30D - 55 films can further be 55 mity21 . The content uniformity was improved by increasing 
improved by mixing it with Eudragit NE 30 D , but the drug the pellet loading up to 70 % and became independent of the 
release during the buffer stage might fail to comply with the filler particle size due to the formation of a percolating 
USP requirements 10 . Films made with Eudragit L30D - 55 , cluster of pellets which prevented segregation during com 
only , were too brittle to resist compression induced damage pression . At this high loading level , the preparation of tablets 
despite plasticization with TEC and relatively high coating 60 became problematic and was only possible when fillers with 
level ( 25 % ) . Pellets coated with Kollicoat 30D MAE 30 DP high binding capacity were utilized . However , tablets con 
alone lost their enteric properties after compression because taining 10 % w / w pellets exhibited high variations in drug 
of the brittle character of this polymer , but a mixture of content and failed the USP requirements for content unifor 
Kollicoat 30D MAE 30 DP and Kollicoat EMM 30D pro mity . 
vided sufficient protection in acidic media ! l . Altaf and 65 Alternatively , enteric pellets may be embedded into tab 
coworkers reduced the fracture of Aquacoat ECD - 30 coats let - shaped plugs by alternate pouring of a molten carrier and 
by spray coating the pellet with an additional PEO layer12 . the pellets into molds with cavities22 . The reported process 
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was manual , discontinuous and needed to be interrupted to The terms “ therapeutic compound ” , “ drug ” and “ active 
allow the carrier to solidify and prevent pellet sedimenta - pharmaceutical ingredient ” are used interchangeably to refer 
tion . The study was further limited to polyethylene glycol as to chemical entities that display certain pharmacological 
the carrier and a pellet load of 8 - 12 % in the matrix . effects in a body and are administered for such purpose . 
Thermal processing in general , and hot - melt extrusion in 5 Non - limiting examples of therapeutic compounds 
particular , have been adopted from the plastics industry to include , but are not limited to , antibiotics , analgesics , vac 
manufacture matrix systems for pharmaceutical purposes . cines , anticonvulsants ; anti - diabetic agents antifungal 
The therapeutic compound is usually included as a powder agents , antineoplastic agents , anti - parkinsonian agents , anti 
or granules into the formulation and dispersed in a molten rheumatic agents , appetite suppressants , biological response 
thermoplastic carrier such as waxes or polymers during 10 modifiers , cardiovascular agents , central nervous system 
processing . The thermal processes involve elevated tem - stimulants , contraceptive agents , dietary supplements , vita 
peratures and the application of shear forces . Hot - melt mins , minerals , lipids , saccharides , metals , amino acids ( and 
extrusion is commonly utilized for the preparation of solid precursors ) , nucleic acids and precursors , contrast agents , 
dispersions of poorly soluble compounds . Depending on the diagnostic agents , dopamine receptor agonists , erectile dys 
solid state of the drug and the number of distinguishable 15 function agents , fertility agents , gastrointestinal agents , hor 
phases in the extrusion product , solid solutions , amorphous mones , immunomodulators , antihypercalcemia agents , mast 
mixtures or solid suspensions have been described in the cell stabilizers , muscle relaxants , nutritional agents , oph 
scientific literature . In most cases , the drug particles undergo thalmic agents , osteoporosis agents , psychotherapeutic 
particle size reduction , melting and / or dissolution in situ , agents , parasympathomimetic agents , parasympatholytic 
resulting in modified properties of the active compound in 20 agents , respiratory agents , sedative hypnotic agents , skin 
the solid dispersion when compared to the bulk material . and mucous membrane agents , smoking cessation agents , 
Amorphization , particle size reduction and hydrophilic coat - steroids , sympatholytic agents , urinary tract agents , uterine 
ing with the carrier material are the most relevant explana - relaxants , vaginal agents , vasodilator , anti - hypertensive , 
tions for the increased dissolution profiles observed for most hyperthyroids , anti - hyperthyroids , anti - asthmatics and ver 
solid dispersions . A patent filed by Miller , et al . , discloses a 25 tigo agents . In certain embodiments , the one or more thera 
formulation and preparation method by hot - melt extrusion to peutic compounds are water - soluble , poorly water - soluble 
disaggregate secondary agglomerates of crystalline or amor - drug or a drug with a low , medium or high melting point . 
phous pre - manufactured drug particles and disperse the The therapeutic compounds may be provided with or with 
individual particles in a carrier under prevention of solid out a stabilizing salt or salts . 
state changes or reaggregation during processing or stor - 30 As used herein , the term “ friability ” refers to the tendency 
age < . Upon solidification , the material may be ground into for the multi - particulates or particles of the present invention 
powders for post - processing or cut into tablets , mini - rods or to disintegrate , break , rupture or for coatings to rub - off or 
cylinders for post spheronization . Drug release kinetics is break - off from attrition during processing or handling . In the 
controlled mainly by the swelling and erosion kinetics of the present invention , if such friability of the multi - particulates 
carrier material , by the geometry of the dosage form and by 35 occurs , such particles will fail to provide the required 
the particle size and solid state of the active compound . therapeutic compound ( or drug ) release and the dosage form 
As a first step , the modified release multi - particulates will be unusable . The present invention provides a signifi 
comprising the therapeutic compound are prepared . Next , cant advantage over the prior art because the thermal con 
these modified release multi - particulates are blended with ditions selected for the co - extrusion of the thermal matrix 
one or more extrudable agents and are extruded , e . g . , 40 and the multi - particulates reduce or mostly eliminate the 
hot - melt extruded , into a final formulation in which at least friability of the multi - particulates extruded into the extrusion 
50 , 60 , 70 , 80 , 90 or a higher percentage of the modified matrix , thereby having the advantage of combining the 
release multi - particulates release their active or therapeutic release profiles of both the extruded matrix and the multi 
agent with the same or equivalent release profile as before particulate . In certain cases , the friability of the multi 
the extrusion upon release from the extrusion matrix . Alter - 45 particulate will be determined by the manner in which the 
natively , the drug release may additionally be controlled by multi - particulate was processed or formed , the manner in 
the nature of the extruded matrix . For example , if the final which the multi - particulates were coated or composition of 
formulation includes an extrudable matrix that releases the the coating ( if any ) . Accordingly , the composition of the 
modified release multi - particulates after , e . g . , traversing the coating ( or shell ) , e . g . , the powder ( s ) , shell ( s ) , coating ( s ) , 
stomach , the release of the active ingredient will be con - 50 binder ( s ) , polymer ( s ) and or excipient ( s ) are selected so that 
trolled by the matrix and by the properties of the modified the finished product has at least a moderate amount of 
release multi - particulates . resistance to chipping , breakage , attrition , friction , and the 
As used herein , the term “ multi - particulates ” refers to one like . Material selections for achieving this are known in the 
or more unit dosage systems such as , but not limited to , art and are further described in the Examples . 
pellets , beads , spheres , mini - tablets , seeds , spheroids or 55 Various methods of preparation may be used to manufac 
granules with modified drug release profile . The multi ture the drug containing particles and high mechanical 
particulates comprise a drug - release controlling and / or drug - strengths are not necessary . Exemplary methods of prepa 
protecting film or matrix , such as a polymeric film or matrix , ration comprise wet - mass extrusion and spheronization , wet 
whose intactness or efficiency is susceptible to certain granulation and spray layering . Other methods including hot 
conditions such as heat or mechanical forces that may occur 60 melt extrusion , compression molding or similar thermal 
during post - processing . The expression “ core material ” processes can be used . 
describes the nature of the interior part of multi - particulates A polymeric coat may be applied to the core material to 
that may also comprise a functional coat . Exemplary “ core modify the drug release and / or to separate the drug from its 
materials ” may be pellets ( spherical matrix systems that environment for protection . The coating level should be 
contain a drug and further excipients ) , granules ( less spheri - 65 greater than 10 % and , more preferably , greater than 20 % 
cal particles that are almost entirely composed of drug ) or w / w polymer weight gain , to ensure its stability during 
nonpareils ( spherical particles without drug ) . thermal processing . The application of polymers with glass 
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transition temperatures that are higher than the thermal ening , deformation , dissolution in the carrier polymer or 
processing temperature may be necessary to prevent in - situ chemical degradation whose likelihood increases as a func 
softening of the coat . However , optimization of the formu - tion of temperature . Low melt - viscosity to provide low 
lation will minimize the period of exposure of the multi resistance against the rotation of the screw during hot - melt 
particulates to elevated temperature and render this require - 5 extrusion and to minimize the shear forces exerted on the 
ment redundant . Optionally , an additional water - soluble or multi - particulates . Good flowability in the solid state and 
acid soluble coat may be applied on top of the release - low melt - viscosity to facilitate rapid transit through the 
modifying coat to act as a barrier between the release - extruder barrel and reduce the residence time of the com 
modifying coat and the carrier matrix . Non - limiting position inside the extruder barrel and hence the time of 
examples of polymers that may be included in the top coat 10 material exposure to elevated temperatures . Especially prill 
are hydroxypropyl cellulose , hypromellose , hydroxyethyl grades yield excellent flowability . Similarity with the multi 
cellulose , methylcellulose , carboxymethylcellulose sodium , particulates regarding particle size , spherical shape and true 
dimethylaminoethyl methacrylate methylmethacrylate density to avoid blend segregation and ensure content uni 
copolymer , chitosan , polyvinyl alcohol or polyvinylpyrroli formity of the final product . A low degree of intermolecular 
done . 15 interaction with the excipients in the multi - particulates that 
All excipients and therapeutic compounds present in the get in direct contact with the thermoplastic carrier during 
multi - particulates should further exhibit sufficient thermal extrusion . 
stability under the applied temperatures . The resulting matrix system can be produced in strands , 
Particle size requirements for the multi - particulates cylinders , tablets , hollow tubes or films . Post - processing 
depend strongly on the selected method and processing 20 may include various product - shaping technologies such as 
conditions and , in the case of hot - melt extrusion , on the pelletization or other cutting techniques , calendering , mold 
configuration of the extrusion equipment . Particles not ing or spheronization to produce a dosage form of the 
exceeding about 800 um with a preferred size range of about desired geometry . 
300 - 500 um are most suitable for processing by hot - melt T he final dosage form will exhibit properties that are 
extrusion . Single screw extruders may have certain advan - 25 comparable to the unprocessed multi - particulates in terms of 
tages over twin - screw extruders , however , the goal is to controlled release of the drug and / or its protection from 
preserve the original particle characteristics during thermal environmental influences . As used herein , the terms “ modi 
processing . fied release ” and “ controlled release ” are interchangeable 
The carrier matrix comprises at least one thermoplastic and intended to describe immediate , extended or delayed 
polymer or meltable lipid , and may also contain further 30 drug release profiles as used in the USP 3144 and necessitates 
functional excipients such as disintegrants , glidants , plasti - the presence of a release controlling element . The release 
cizers , antioxidants , retardants or other release - modifying controlling element may be a functional coat and / or may be 
agents , surfactants , stabilizing agents or processing aids . provided by the matrix material . 
The term “ matrix " relates to the material surrounding the The present invention further discloses a formulation and 
multi - particulates to provide a multi - particulate dosage 35 a method of preparation for the hot - melt extrusion of enteric 
form . matrix pellets . The pellets as described in the present inven 
The term , " thermoplastic ” when describing a polymer tion have an average particle size between 500 and 3000 um , 
refers to one or more polymers that melt and / or soften when preferably between 500 and 1000 um and comprise a 
heat is applied to allow molding while maintaining good pharmaceutically active substance ( drug ) in a plasticized , 
chemical stability . Exemplary thermoplastic polymers that 40 anionic polymer matrix . The herein disclosed pellets release 
may be used as matrix material include , but are not limited less than 10 % of the drug after 2 hours in simulated gastric 
to , poly ( ethylene oxide ) - polypropylene oxide ) copolymer , fluid pH 1 . 2 , and more than 40 % after an additional 2 hours 
poly ( ethylene glycol ) , poly ( ethylene oxide ) , poly ( vinyl in buffer pH 6 . 8 or 7 . 4 , respectively . The herein disclosed 
alcohol ) , carbomer , polycarbophil , cellulosic derivatives , pellets further exhibit high mechanical strength and low 
natural gums , povidone , poly ( vinyl acetate ) , alginates , 45 friability that makes them more suitable for post - processing 
acrylic and methacrylic polymers . Lipids include waxes than pellets prepared by traditional methods . Examples for 
such as beeswax , carnauba wax , glycerides ( mono , di - and post - processing comprise functional film coating , direct 
tri - ) , GMS , GMO , sucrose stearate . It is contemplated and compression , filling into capsules and melt extrusion into 
within the scope of the invention that a combination of monolithic systems .
appropriate polymers and / or lipids may be used as matrix 50 Anionic polymers contain anionic groups that are proto 
material in form of copolymers or physical blends . nated during the acidic stage , but ionize after pH increase . 
The multi - particulates may be blended with the carrier The anionic polymer that is used as the release controlling 
polymer prior to extrusion , or be dosed to the carrier during matrix is insoluble at low pH and exhibits a low permeability 
the extrusion process using a separate port along the barrel . for the drug in the acidic stage of dissolution testing . During 
Feeding the multi - particulates over a port that is located in 55 the buffer stage , ionization of the acidic groups of the 
the vicinity of the die zone may reduce the exposure of the polymer will increase the drug release by matrix swelling 
particles to thermal stress and shear forces and may promote and / or erosion . Especially suitable are copolymers of meth 
the physical and functional intactness of the multi - particu - acrylate and methacrylic acid of varying ratios ( Eudragit S 
lates . and Eudragit L ) or mixtures thereof . 
Under the conditions of thermal processing , the multi - 60 Pharmaceutically acceptable anionic polymers used for 
particulates must remain generally physically intact so that the melt extrusion process possess high glass transition 
the drug release characteristics of the original particles are temperatures and high melt viscosities at processing condi 
preserved in the matrix product . This is achieved by utilizing tions . According to the invention , acceptable plasticizers or 
a carrier polymer that meets one or more of the following plasticizer mixtures are added to the formulation in sufficient 
requirements : Melting or softening at relatively low tem - 65 amount to decrease the glass transition temperature and the 
peratures so that the integrity of the multi - particulates is not melt viscosity of the polymer to avoid thermal degradation 
compromised by thermally induced processes such as soft - as occurring at elevated processing temperatures . Accept 
14 
stage . 
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able plasticizers are non - toxic and regarded as safe , exhibit cellulose were placed in a bowl and thoroughly premixed for 
high plasticization efficiency for the anionic polymer and do 10 minutes . The PVP K25 was dissolved in the water , and 
not increase the drug release above 10 % during the acidic this binder solution is added dropwise to the powder under 
stirring . The wet - massed material was then transferred into 
The pellets may comprise one or several pharmaceutically 5 a LCI Benchtop granulator and extruded through a 0 . 6 mm 
active substances at a combined level of about 0 . 1 to 70 % , screen at a rotation blade speed of 50 rpm . The extruded 
preferably 5 to 40 % drug . The pellet formulation may strands were placed in a Caleva Model 120 Spheronizer and further comprise additional excipients and / or processing rotated at 700 rpm for 3 minutes . The obtained pellets were aids improving the chemical stability , processibility or dried in a 40° oven for 24 hours and sieved . The fraction release properties of the pellets such as thermal lubricants , 1s , 10 between 300 and 500 um was used for subsequent enteric glidants and / or antioxidants . coating The process of hot - melt extrusion of the present invention 
is advantageous over traditional pellet preparation methods 
since it is a one - step , continuous process avoiding the use of TABLE 2 
solvents or labor - intensive drying procedures . The compo Formulation for the preparation of pellets . 
nents of the disclosed composition may be reduced in 15 
particle size and / or blended prior to extrusion utilizing Component Quantity [ g ] Percentage 
commonly available milling and mixing equipment . Com 
90 . 0 Anhydrous theophylline monly used single or twin screw extruders of varying sizes 30 . 0 % Microcrystalline cellulose ( PH101 ) 187 . 5 62 . 5 % and with one or several temperature zones may be used PVP K25 22 . 5 7 . 5 % 
according to the invention . The temperature of at least one 20 Water dest . 180 . 0 
of the heating zones must be selected to be at least 10 , 
preferably at least 30° C . above the glass transition tem 
perature of the plasticized polymer to produce a polymer 
melt of sufficiently low melt viscosity . The extrusion tem EXAMPLE 3 
perature must further be below the thermal degradation 25 
temperature of the polymer or of the other formulation Drug Layering of Nonpareils 
components . The diameter and shape of the extruded strand 
is primarily governed by the diameter and geometry of the Active layered nonpareils of the desired particle size 
die orifice . but may also be influenced by the viscoelastic range were prepared utilizing the following procedure . 
properties of the polymeric melt . Circular dies with diam 
eters between 500 and 1000 um are preferred according to TABLE 3 
the present invention . The extruded strands may be cut into Coating dispersion for 30 % drug weight gain of a 250 g batch . cylindrical pellets in the hot state or after cooling to room 
temperature and may further be spheronized . Several tech Component Quantity [ g ] 
nologies have been developed for the subsequent pellitiza 
tion and spheronization in a continuous or semi - continuous 35 Anhydrous theophylline 75 . 0 
manner25 - 27 . HPMC E3 ( Pharmacoat 603 ) 8 . 0 Talc 20 . 0 The terms “ enteric dissolution testing ” and “ enteric drug Water dest . 425 . 3 release ” are interpreted as described in USP 31 chapter 
< 711 > for delayed - release dosage forms24 . 
The term " extended drug release ” is used as described in 40 A 250 g batch of nonpareils made of 100 % microcrystal 
USP chapter < 711 > for extended - release dosage forms24 . line cellulose NF and having a particle size of 300 - 500 um 
( Celphere® CP 305 , Asahi Kasei America , Inc . ) were intro 
EXAMPLE 1 duced in a Strea - 1 fluidized bed coater ( Aeromatic - Fielder ) 
and layered with an aqueous dispersion of Theophylline and 
Core Materials - HPMC E3 applying the following conditions : 
TABLE 4 
TABLE 1 Process parameters for Strea - 1 fluidized bed coater ( Aeromatic - Fielder ) . 
30 
Examples for core materials that may be used for the preparation 
of modified release multi - particulates . ( Moisture content determined 
as loss on drying of coated , cured particles after equilibration at 
22 • 1° C . and 50 + 5 % RH ( n = 3 ) . ) 
Batch size 
Theoretical drug weight gain 









1 . 5 - 1 . 8 bar 
3 - 6 
1 . 0 mm 
75 - 80° C . 
45 - 50° C . 
2 . 0 g / min or 8 . 0 g / min * kg 
bottom , Wurster column 
Core Material Supplier 
Theophylline 
Content [ % ] 
Moisture 
Content [ % ] 
- 55 
99 . 5 
30 . 0 
2 . 15 + 0 . 13 
3 . 52 + 0 . 08 
Drug Granules BASF 
Pellets Self - made according 
to example 2 
MCC Spheres Asahi Kasei 
( Celphere ® CP - 305 ) 
10 . 8 3 . 50 + 0 . 25 The obtained layered particles were dried ( 24 hours in 40° 
C . oven ) and sieved prior to enteric coating . 
EXAMPLE 4 
EXAMPLE 2 
Enteric Coating of Core Material 
Preparation of Pellets 
65 
The following procedure may be used to prepare pellets of 
the desired particle size . The drug and microcrystalline 
The following formulation and processing method may be 
employed to provide the core material ( pellets , granules , 
nonpareils ) with an enteric coat . Alternative functional poly 
16 
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mers , plasticizers or anti - tacking agents may be used . The Electron , Germany ) may be used for the preparation of the 
film coated particles may be dried overnight in a 40° C . oven drug loaded , polymeric strands , which were then cut to 
or inside the coater , sieved and the 300 - 500 um particle size obtain cylindrical pellets . The pellets may be spheronized in 
fraction may be used for subsequent hot - melt extrusion . a subsequent step employing appropriate spheronization 
5 equipment . 
TABLE 5 
TABLE 7 Coating dispersion for 200 g batch . 
Examples for the formulation of enteric matrix pellets . 
Formulation Percentage Amount [ g ] 
10 
Eudragit ® L30D - 55 Extrusion 12 % polymer in dispersion Plasticizer Eudragit ® 400 ( 120 g Amount S 100 polymer ) Theophylline Temperature 
TEC Plasticizer 10 % based on polymer content 12 [ % ] [ % ] [ % ] [ °C . ] 
GMS 7 . 5 % based on polymer content none 220 
Tween 80 40 % based on GMS 3 . 6 TEC 180 Water 575 . 4 15 TEC 50 140 Solid content 14 . 46 % PEG 8000 60 180 
PEG 8000 50 140 
Methylparaben 180 
Methylparaben 50 140 
TABLE 6 
9 





20 Process parameters for functional coating in a Strea - 1 fluidized bed coater 
( Aeromatic - Fielder ) . EXAMPLE 6 
Weight gain 20 - 50 % 
Inlet temperature 36 - 38° C . In Vitro Method Drug Release Testing of Enteric 
Exhaust temperature 32 - 33° C . Matrix Pellets 
Nozzle diameter 1 . 0 mm 25 
Spray rate 10 g / ( min * kg ) The drug release properties from the pellets may be 
Set - up Wurster , bottom spray determined as described in USP 31 , method < 711 > for 
delayed - release dosage forms method A . A paddle set - up 
Additional polymeric top coats may be applied to the apparatus 2 ) was employed with a water bath to maintain 
enteric coated multi - particulates to improve their resistance 30 the media temperature at 37 + 0 . 5° C . and the paddle speed set 
to high temperatures and / or shear forces during the subse to 50 rpm . The formulations were placed in 750 ml simu 
quent hot - melt extrusion process . lated gastric fluid pH 1 . 2 ( without pepsin , referred to as acid 
stage ) for 2 hours and an aliquot of the fluid was withdrawn 
EXAMPLE 5 at the end of this period . A volume of 250 ml 0 . 20 M tribasic 
35 sodium phosphate that had been equilibrated to 37 + 0 . 5° C . 
Hot - Melt Extrusion of Enteric Matrix Pellets was added after 2 hours to raise the pH of the media to 6 . 8 
or 7 . 4 , respectively ( buffer stage ) . After expiration of the 
The following formulations and procedure may be used to testing period , the remaining particles were completely 
prepare enteric matrix pellets of the desired particle size destroyed by mixing with a high shear homogenizer to 
Powder blends for extrusion were prepared by pre - mixing 10 completely release residual drug , an aliquot of the fluid was 
the polymer with the plasticizer and subsequent blending filtered and analyzed to determine the total amount released 
with the drug using appropriate mixing equipment . A mini using a validated HPLC method . All average values were 
extruder equipped with two co - rotating screws and a circular obtained from at least n = 3 and were reported as % released 
500 um die ( Haake Minilab , Rheomax CTW5 , Thermo from the total amount released . 
TABLE 8 
Drug release of melt extruded pellets ( formulations 














10 hrs Formulation 
27 . 2 81 . 3 98 . 8 
28 . 3 77 . 5 92 . 8 
13 . 9 13 . 9 90 . 2 97 . 7 97 . 7 
10 % Theophylline 
75 % HPMC AS LF 
15 % TEC 
10 % Theophylline 
78 . 2 % HPMC AS LF 
11 . 8 % PEO 200K 
10 % Theophylline 
60 % HPMC AS LF 
15 % Ethylcellulose 
15 % ATBC 
10 % Theophylline 
75 % HPMC AS HF 
15 % TEC 
10 % Theophylline 
78 . 2 % HPMC AS HF 
11 . 8 % ATBC 
10 % Theophylline 
69 . 2 % Eudragit L100 
20 . 8 % TEC 
22 . 2 22 . 2 97 . 2 99 . 5 99 . 5 
14 . 8 92 . 1 98 . 8 
3 . 8 3 . 8 31 . 3 61 . 1 61 . 1 
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TABLE 8 - continued 
Drug release of melt extruded pellets ( formulations 














10 hrs Formulation 
4 . 2 35 . 9 68 . 0 95 . 0 
6 . 1 47 . 0 83 . 5 99 , 9 
5 . 4 50 . 4 50. 4 86 . 2 99 . 9 
7 . 1 51 . 8 89 . 7 99 . 9 
7 . 7 59 . 7 95 . 6 99 . 9 
5 . 8 32 . 9 63 . 7 84 . 5 84 . 5 91 . 9 91 . 9 97 . 0 97 . 0 98 . 8 98 . 8 
10 % Theophylline 
69 . 2 % Eudragit $ 100 
20 . 8 % TEC 
10 % Theophylline 
64 . 3 % Eudragit S100 
25 . 7 % TEC 
20 % Theophylline 
57 . 1 % Eudragit S100 
22 . 9 % TEC 
30 % Theophylline 
50 % Eudragit S100 
20 % TEC 
40 % Theophylline 
42 . 9 % Eudragit S100 
17 . 1 % TEC 
30 % Theophylline 
50 % Eudragit S100 
20 % ATBC 
30 % Theophylline 
50 % Eudragit $ 100 
20 % PEG 8000 
30 % Theophylline 
50 % Eudragit S100 
20 % methylparaben 
30 % Theophylline 
70 % Eudragit 100 
30 % Theophylline 
60 % Eudragit S100 
10 % TEC 
30 % Theophylline 
60 % Eudragit $ 100 
10 % PEG 8000 
30 % Theophylline 
60 % Eudragit S100 
10 % methylparaben 
83 . 2 90 . 7 99 . 4 
3 . 9 61 . 6 97 . 8 
5 . 9 31 . 3 56 . 1 81 . 6 92 . 3 97 . 8 98 . 8 
4 . 2 28 . 2 52 . 3 72 . 0 84 . 1 90 . 7 95 . 4 
18 . 2 41 . 3 72 . 4 72 . 4 90 . 5 90 . 5 97 . 3 98 . 5 99 . 2 0. < 
5 . 7 5 . 7 36 . 7 36 . 7 60 . 9 60 . 9 81 . 81 . 5 90 . 5 96 . 4 98 . 2 
EXAMPLE 7 
Hot - Melt Extrusion of the Modified Release 
Multi - Particulates 
The following is an example for the hot - melt extrusion of 
a monolithic matrix with embedded enteric particles utiliz 
ing a Randcastle Microtruder RCP - 0750 . Various carrier 
polymers may be used , and the loading of multi - particulates 
may be varied . TABLE 9 
iler 
Multi - particulates and the polymer were blended in a 
V - shell blender or alternative blending device . The formu 
lation exhibits excellent flow properties and was fed through 
a hopper into the barrel by gravitational forces only without 
additional force feeding . The separation of the blend com 
ponents inside the hopper or extruder was reduced due to the 
spherical nature of the particles and similarities in particle 
size and true density . The following processing conditions 
0 are used for the employed extruder . Variations in extrusion 
equipment , screw speed , temperature settings and motor 
load / torque are possible . 
TABLE 10 
Composition for the hot - melt extrusion of a multi - particulate matrix . 
Component Quantity [ g ] 
50 
Modified Release Multi - particulates 
Carrier polymer 
30 . 0 
70 . 0 
Examples of carrier polymers and extrusion conditions 
using a Randcastle Microtruder RCP - 0750 . 
Melting Extrusion Temperature [ ° C . ] 
Polymer Supplier & Grade P oint [ ° C . ] Zone 1 Zone 2 Zone 3 Die 
Poloxamer 188 
NF Prill 
BASF , Lutrol F68 
BASF , Lutrol F127 
57 . 1 + 0 . 3 








48 Poloxamer 407 
NF Prill 
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TABLE 10 - continued 
Examples of carrier polymers and extrusion conditions 
using a Randcastle Microtruder RCP - 0750 . 
Melting Extrusion Temperature ( °C . ] 
Polymer Supplier & Grade P oint [ ° C . ] Zone 1 Zone 2 Zone 3 Die 
63 . 8 1 0 . 3 40 45 50 50 









Dow , Carbowax 
Sentry PEG 4000 
Dow , Carbowax 
Sentry PEG 8000 
Dow , Sentry Polyox 
WSR N10 
Dow , Sentry Polyox 
WSR N80 
69 . 7 + 0 . 2 u 8 ? ? du
69 . 9 + 0 . 8 55 8 ? 
EXAMPLE 8 speed of 2 . 5 mm / min . The load - deflection data was collected 
using Chatillon Nexygen TCD force testing software . The 
Direct Compression of Multi - Particulates mechanical strength was reported as the tensile strength and 
20 calculated using the following equation : 
Functionally coated particles ( 30 % ) , microcrystalline cel 
lulose ( CeolusTM KG - 802 , 65 % ) and superdisintegrant ( Ac 
Di - Sol® , 5 % ) may be directly compressed into round tablets 
( 333 mg , equivalent to 100 mg particles ) using a single 
station manual Carver Press equipped with a concave , 10 25 
mm diameter die . The compression force was 5 kN and the Specimens with diameters ( d ) equaling the length ( 1 ) were 
tablet hardness was 17 . 1 – 1 . 6 KP . selected for the experiments , and the maximum load ( P ) at 





In Vitro Method Drug Release Testing of Enteric TABLE 11 
Multi - Particulates and Hot - Melt Extruded Matrices 
Tensile strength of melt extruded Eudragit ® S100 
The drug release properties from the particles or hot - melt pellets containing 30 % theophylline as a function of plasticizer 
type and level . Diametral compression analysis of individual extruded matrices may be determined as described in USP 35 pellets ( mean SD , n = 6 ) . 31 , method < 711 > for delayed - release dosage forms method 
A . A paddle set - up ( apparatus 2 ) was employed with a water PEG 8000 
bath to maintain the media temperature at 37 + 0 . 5° C . and the Methylparaben TEC Tensile 
paddle speed set to 100 rpm . The formulations were placed Plasticizer Tensile Strength Tensile Strength Strength + Concentration SD [ MPa ] SD [ MPa ] in 750 ml simulated gastric fluid pH 1 . 2 ( without pepsin , 40 
referred to as acid stage ) for 2 hours and an aliquot of the 0 % 40 . 4 5 . 2 40 . 4 = 5 . 2 40 . 4 + 5 . 2 
10 % fluid was withdrawn at the end of this period . A volume of 30 . 0 3 . 0 33 . 6 + 2 . 1 27 . 0 + 1 . 7 20 % 29 . 5 = 4 . 5 29 . 7 + 2 . 4 17 . 4 + 3 . 4 250 ml 0 . 20 M tribasic sodium phosphate that had been 
equilibrated to 37 + 0 . 5° C . was added after 2 hours to raise 
the pH of the media to 6 . 8 or 7 . 4 , respectively ( buffer stage ) . 45 
After expiration of the testing period , the remaining particles TABLE 12 
were completely destroyed by mixing with a high shear 
homogenizer to completely release residual drug , an aliquot Tensile strength of uncoated core material and coated multi - particulates . Diametral compression analysis of of the fluid was filtered and analyzed to determine the total individual pellets ( mean + SD , n = 20 ) . 
amount released using a validated HPLC method . All aver - 50 
age values were obtained from at least n = 3 and were Before Coating After Coating 
reported as % released from the total amount released . Tensile Strength Tensile Strength = SD [ MPa ] SD [ MPa ] The dissolution behavior of the multi - particulates before 
and after extrusion into monolithic matrices is shown in Granules 7 . 3 + 2 . 2 9 . 5 = 2 . 8 
Pellets FIGS . 2 - 5 . 21 . 5 = 3 . 0 20 . 0 3 . 4 MCC Spheres 33 . 6 + 5 . 4 24 . 1 + 4 . 5 
EXAMPLE 10 
It is contemplated that any embodiment discussed in this 
Determination of the Tensile Strength of specification can be implemented with respect to any 
Multi - Particulates 60 method , kit , reagent , or composition of the invention , and 
vice versa . Furthermore , compositions of the invention can 
The mechanical strength of the core material , coated be used to achieve methods of the invention . 
multi - particulates and hot - melt extruded pellets was deter It will be understood that particular embodiments 
mined using a Chatillon Universal Tension / Compression described herein are shown by way of illustration and not as 
tester model TCD - 200 . A flat circular steel plate was fitted 65 limitations of the invention . The principal features of this 
onto a DFGS 50 digital force gauge and lowered in diametral invention can be employed in various embodiments without 
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the art will recognize , or be able to ascertain using no more WO 2008 / 101743 : Pellets comprising an active substance 
than routine experimentation , numerous equivalents to the matrix resistant to gastric juice . Gryczke , A . ( 2008 ) . 
specific procedures described herein . Such equivalents are 1 . Young , C . R . , Koleng , J . J . , Ginity , J . W . M . Properties of 
considered to be within the scope of this invention and are drug - containing spherical pellets produced by a hot - melt 
covered by the claims . extrusion and spheronization process . Journal of Micro 
All publications and patent applications mentioned in the encapsulation 20 : 613 - 625 ( 2003 ) . 
specification are indicative of the level of skill of those 2 . Young , C . R . , Dietzsch , C . , McGinity , J . W . Compression 
skilled in the art to which this invention pertains . All of Controlled - Release Pellets Produced by a Hot - Melt publications and patent applications are herein incorporated Extrusion and Spheronization Process . Pharmaceutical 
by reference to the same extent as if each individual publi - 10 Development & Technology 10 : 133 - 139 ( 2005b ) . 
cation or patent application was specifically and individually 3 . Follonier . N . Doelker . E . Cole . E . T . Evaluation of 
indicated to be incorporated by reference . hot - melt extrusion as a new technique for the production The use of the word “ a ” or “ an ” when used in conjunction of polymer - based pellets for sustained release capsules with the term " comprising ” in the claims and / or the speci 
fication may mean " one , ” but it is also consistent with the 15 containing high loadings of freely soluble drugs . Drug 
meaning of “ one or more , " " at least one , ” and “ one or more Development and Industrial Pharmacy 20 : 1323 - 1339 
than one . ” The use of the term “ or ” in the claims is used to ( 1994 ) . 
mean " and / or ” unless explicitly indicated to refer to alter 4 . de Brabander , C . , Vervaet , C . , Remon , J . P . Development 
natives only or the alternatives are mutually exclusive , and evaluation of sustained release mini - matrices pre 
although the disclosure supports a definition that refers to 20 pared via hot melt extrusion . Journal of Controlled 
only alternatives and " and / or . ” Throughout this application , Release 89 : 235 - 247 ( 2003 ) . 
the term “ about ” is used to indicate that a value includes the 5 . Young , C . R . , Crowley , M . , Dietzsch , C . , McGinity , J . W . 
inherent variation of error for the device , the method being Physicochemical properties of film - coated melt - extruded 
employed to determine the value , or the variation that exists pellets . Journal of Microencapsulation 24 : 57 - 71 ( 2007 ) . 
among the study subjects . 25 6 . U . S . Pat . No . 5 , 552 , 159 : Solid depot drug form . Mueller , 
As used in this specification and claim ( s ) , the words W . , Spengler , R . , Grabowski , S . , Sanner , A . ( 1996 ) . 
" comprising ” ( and any form of comprising , such as “ com - 7 . Oshlack , B . , Huan , H . - P . , Chasin , M . ( 2001 ) US 2001 / 
prise ” and “ comprises ” ) , “ having ” ( and any form of having , 0033865 . Melt - extrusion multiparticulates . 
such as “ have ” and “ has ” ) , “ including ” ( and any form of 9 . Lundqvist . A . E . K . , Podczeck . F . & Michael Newton , J . 
including , such as “ includes ” and “ include ” ) or “ containing ” 30 Compaction of , and drug release from , coated drug pellets ( and any form of containing , such as " contains ” and “ con mixed with other pellets . European Journal of Pharma tain ” ) are inclusive or open - ended and do not exclude ceutics and Biopharmaceutics 46 , 369 - 379 ( 1998 ) . additional , unrecited elements or method steps . 10 . Beckert , T . E . , Lehmann , K . , Schmidt , P . C . Compres The term “ or combinations thereof ” as used herein refers 
to all permutations and combinations of the listed items 35 sion of enteric - coated pellets to disintegrating tablets . International Journal of Pharmaceutics 143 , 13 - 23 ( 1996 ) . preceding the term . For example , " A , B , C , or combinations 
thereof is intended to include at least one of : A , B , C , AB , 11 . Dashevsky , A . , Kolter , K . , Bodmeier , R . Compression of 
AC , BC , or ABC , and if order is important in a particular pellets coated with various aqueous polymer dispersions . 
context , also BA , CA , CB , CBA , BCA , ACB , BAC , or CAB . International Journal of Pharmaceutics 279 , 19 - 26 ( 2004 ) . 
Continuing with this example , expressly included are com - 40 12 . Altaf , S . A . , Hoag , S . W . , Ayres , J . W . Bead compacts . II . 
binations that contain repeats of one or more item or term , Evaluation of rapidly disintegrating nonsegregating com 
such as BB , AAA , MB , BBC , AAABCCCC , CBBAAA , pressed bead formulations . Drug Dev Ind Pharm 25 , 
CABABB , and so forth . The skilled artisan will understand 635 - 642 ( 1999 ) . 
that typically there is no limit on the number of items or 13 . Vergote , G . J . , Kiekens , F . , Vervaet , C . , Remon , J . P . Wax 
terms in any combination , unless otherwise apparent from 45 beads as cushioning agents during the compression of 
the context . coated diltiazem pellets . European Journal of Pharmaceu 
All of the compositions and / or methods disclosed and tical Sciences 17 , 145 - 151 ( 2002 ) . 
claimed herein can be made and executed without undue 14 . Debunne , A . , Vervaet , C . & Remon , J . - P . Development 
experimentation in light of the present disclosure . While the and in vitro evaluation of an enteric - coated multiparticu 
compositions and methods of this invention have been 50 late drug delivery system for the administration of piroxi 
described in terms of preferred embodiments , it will be cam to dogs . European Journal of Pharmaceutics and 
apparent to those of skill in the art that variations may be Biopharmaceutics 54 , 343 - 348 ( 2002 ) . 
applied to the compositions and / or methods and in the steps 15 . Debunne , A . , Vervaet , C . , Mangelings , D . , Remon , J . - P . 
or in the sequence of steps of the method described herein Compaction of enteric - coated pellets : influence of formu 
without departing from the concept , spirit and scope of the 55 lation and process parameters on tablet properties and in 
invention . All such similar substitutes and modifications vivo evaluation . European Journal of Pharmaceutical Sci 
apparent to those skilled in the art are deemed to be within e nces 22 , 305 - 314 ( 2004 ) . 
the spirit , scope and concept of the invention as defined by 16 . Tunón , A . , Alderborn , G . Granule deformation and 
the appended claims . densification during compression of binary mixtures of 
granules . International Journal of Pharmaceutics 222 , 
REFERENCES 65 - 76 ( 2001 ) . 
17 . Yao , T . , Yamada , M . , Yamahara , H . , Yoshida , M . Tablet 
U . S . Pat . No . 6 , 335 , 033 : Melt - extrusion multiparticulates . ing of Coated Particles . II . Influence of Particle Size of 
Oshlack , B . , Huang , H . - P . , Chasin , M . ( 2002 ) . Pharmaceutical Additives on Protection of Coating Mem 
U . S . Pat . No . 6 , 743 , 442 : Melt - extruded orally administrable 65 brane from Mechanical Damage during Compression 
opioid formulations . Oshlack , B . , Chasin , M . , Huang , Process . Chemical & Pharmaceutical Bulletin 46 , 826 
H . - P . , Sackler , D . ( 2004 ) . 830 ( 1998 ) . 
23 
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18 . Altaf , S . A . , Hoag , S . W . , Ayres , J . W . Bead compacts . I . 2 . The composition of claim 1 , wherein the extruded 
Effect of compression on maintenance of polymer coat thermoplastic polymer matrix comprises at least 80 % intact 
integrity in multilayered bead formulations . Drug Dev Ind multi - particulate pellets by weight . 
Pharm 24 , 737 - 746 ( 1998 ) . 3 . The composition of claim 1 , wherein the extruded 
19 . El - Mandi , I . M . , Deasy , P . B . Tableting of coated 5 thermoplastic polymer matrix is hydrophilic . 
ketoprofen pellets . Journal of Microencapsulation 17 , 4 . The composition of claim 1 , wherein a polymer of the 
133 - 144 ( 2000 ) . extruded thermoplastic polymer matrix has a molecular 
20 . Wagner , K . G . , Krumme , M . , Schmidt , P . C . Investiga C . Investiga - weight of less than 1 , 000 , 000 . tion of the pellet - distribution in single tablets via image 5 . The composition of claim 1 , wherein the multi - particu analysis . European Journal of Pharmaceutics and Biop - 10 1 . late pellets comprise 5 to 70 weight percent of the compo harmaceutics 47 , 79 - 85 ( 1999 ) . sition . 21 . Beckert , T . E . , Lehmann , K . , Schmidt , P . C . Compres 
sion of enteric - coated pellets to disintegrating tablets : 6 . The composition of claim 1 , wherein the multi - particu 
uniformity of dosage units . Powder Technology 96 , 248 late pellets comprise an effective amount of 5 to 80 weight 
254 ( 1998 ) . 15 percent of one or more therapeutic compounds . 
22 . Schmidt , C . , Bodmeier , R . A multiparticulate drug 7 . The composition of claim 1 , wherein the modified 
delivery system based on pellets incorporated into con - release polymer is an enteric drug release polymer . 
gealable polyethylene glycol carrier materials . Interna 8 . The composition of claim 1 , wherein the multi - particu 
tional Journal of Pharmaceutics 216 : 9 - 16 ( 2001 ) . late pellets comprise between 10 % to 60 % ( w / w ) of the 
23 . WO 2007 / 001451 : Stabilized HME composition with 20 modified release polymer . 
small drug particles . Miller , D . , McConville , J . , McGinity , 9 . The composition of claim 1 , wherein the multi - particu 
J . W . , Williams , R . O . III ( 2007 ) . late pellets are film - coated drug granules , film - coated drug 
24 . < 711 > Dissolution . in USP 31 - NF ( 2008 ) . loaded pellets or film - coated drug - layered nonpareils . 
25 . Young , C . R . , Koleng , J . J . , McGinity , J . W . Production 10 . The composition of claim 1 , wherein the multi 
of spherical pellets by a hot - melt extrusion and spheroni - 25 particulate pellets , or a component thereof , does not dissolve 
zation process . International Journal of Pharmaceutics in the extruded thermoplastic polymer matrix . 
242 : 87 - 92 ( 2002 ) . 11 . The composition of claim 7 , wherein less than 10 % of 26 . US 2007 / 0264328 : Continuous melt spheronization the one or more therapeutic compounds will be released in apparatus and process for the production of pharmaceu acidic media from the composition , and wherein 80 % of the tical pellets . Ghebre - Sellassie , I . , Martin , C . , Elliot , B . 30 one one or more therapeutic compounds will be released in ( 2007 ) . media pH above 6 . 8 according to USP 31 , method 711 for 27 . European Patent No . 1563897 Device for producing delayed - release dosage forms method A . round pellets . Rein R . ( 2005 ) . 
What is claimed is : 12 . The composition of claim 1 , wherein the multi 
1 . A modified release pharmaceutical composition com - 35 particulate pellets have an average particle size of from 300 
prising an extruded thermoplastic polymer matrix comprised 03000 
of a poly ( ethylene oxide ) or a poly ( ethylene oxide ) - poly 13 . The composition of claim 12 , wherein the multi 
propylene oxide ) copolymer in which modified release particulate pellets have a particle size of from 300 to 800 um 
and an average particle size of from about 300 to 3000 um . multi - particulate pellets are uniformly disposed , wherein the 
modified release multi - particulate pellets have a particle size 40 14 . The composition of claim 1 , wherein the multi 
of from 300 to 800 um or an average particle size of from particulate pellets have a particle size of from 300 to 800 um . 
300 to 3000 um , and further wherein individual multi 15 . The composition of claim 1 , further defined as a tablet . 
particulate pellets comprise a modified release polymer 16 . The composition of claim 1 , wherein the modified 
matrix or a modified release polymer coating , and also release polymer is further defined as immediate , extended , 
further comprise an effective amount of one or more thera - 45 SUS 15 sustained or delayed release polymer . 
peutic compounds . * * * * * 
